EGFR and non-small cell lung carcinoma: Erlotinib is a highly specific and reversible EGFR-TKI, primarily applied in metastatic NSCLC with tumor epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) mutation 9 [3].